Transcenta Holding has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix.

Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how and regulatory support packages. Transcenta will be eligible to receive a substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies, reflecting the long-term value both companies expect to create through this collaboration.

The HiCB platform is designed to deliver greater process efficiency, improve process control and product consistency, and reduce cost of goods compared to conventional fed-batch manufacturing process, ultimately contributing to expanded global patient access to high-quality and affordable biologics.

 “We are pleased to share our HiCB platform, a result of Transcenta’s leadership in highly intensified continuous bioprocessing, with partners who share our vision of transforming biologics manufacturing. By enabling others to implement HiCB, we can collectively advance affordability of, and global access to innovative biologics. The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best-in-class therapeutics,” said Dr Xueming Qian, Chairman and CEO, Transcenta.

Under this collaboration, EirGenix will adopt Transcenta’s HiCB platform to support its biologics development programmes and manufacturing operations. EirGenix plans to apply the HiCB platform to serve CDMO clients pursuing intensified and continuous manufacturing solutions.

 “This collaboration represents a win–win partnership that combines Transcenta’s innovation in continuous biomanufacturing and EirGenix’s proven bioprocessing and CDMO expertise. Together, we aim to redefine how biologics are made—more efficiently, sustainably, and at lower cost—to reach more patients worldwide,” said Dr L-C Liu, Chairman and President, EirGenix.